Table 2.
Current NK-cell immunotherapy clinical trials for CLL.
| Identifier | Source of NK cells | Phase | Treatment method design |
|---|---|---|---|
| NCT05020678 | Allogeneic | 1 | NKX019 |
| NCT04796688 | AT19 | 1 | CAR-NK-CD19 + Fludarabine and Cyclophosphamide |
| NCT03056339 | Cord blood derived | 1 | iC9/CAR.19/IL15-transduced NK cells + Fludarabine, Cyclophosphamide or Mesna |
| NCT04848064 | Allogeneic | 1 | NK cell infusion + Fludarabine, Cyclophosphamide and Mogamulizumab |
| NCT02727803 | NK92 | 2 | NK92 + cord blood transplant + Chemo + Rituximab |
| NCT02890758 | Non-HLA matched donor | 1 | NK cells + ALT803 |